CO2023007904A2 - Lipocalin Mutein Dry Powder Formulation for the Treatment of Asthma - Google Patents

Lipocalin Mutein Dry Powder Formulation for the Treatment of Asthma

Info

Publication number
CO2023007904A2
CO2023007904A2 CONC2023/0007904A CO2023007904A CO2023007904A2 CO 2023007904 A2 CO2023007904 A2 CO 2023007904A2 CO 2023007904 A CO2023007904 A CO 2023007904A CO 2023007904 A2 CO2023007904 A2 CO 2023007904A2
Authority
CO
Colombia
Prior art keywords
dry powder
powder formulation
asthma
lipocalin mutein
treatment
Prior art date
Application number
CONC2023/0007904A
Other languages
Spanish (es)
Inventor
Mary Fitzgerald
David Robert Close
Philip Gardiner
Robert Alexander Palmér
Marja Riikka Savolainen
Sandra Gracin
Ankur Ajmera
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2023007904A2 publication Critical patent/CO2023007904A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Abstract

La presente invención está relacionada con el tratamiento del asma en un sujeto humano mediante la administración por inhalación oral de una formulación de polvo seco que comprende una cantidad con eficacia terapéutica de una muteína de lipocalina contra el receptor alfa de IL-4 (IL-4Rα), o una variante o fragmento de esta, a dicho sujeto. La invención también está relacionada con la formulación de polvo seco que comprende la muteína de lipocalina contra el receptor alfa de IL-4 (IL-4Rα), o una variante o un fragmento de esta.The present invention relates to the treatment of asthma in a human subject by administration by oral inhalation of a dry powder formulation comprising a therapeutically effective amount of a lipocalin mutein against the IL-4 receptor alpha (IL-4Rα ), or a variant or fragment of it, to said subject. The invention also relates to the dry powder formulation comprising lipocalin mutein against IL-4 receptor alpha (IL-4Rα), or a variant or fragment thereof.

CONC2023/0007904A 2020-12-18 2023-06-16 Lipocalin Mutein Dry Powder Formulation for the Treatment of Asthma CO2023007904A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127903P 2020-12-18 2020-12-18
PCT/EP2021/086730 WO2022129629A1 (en) 2020-12-18 2021-12-20 Lipocalin mutein dry powder formulation for treatment of asthma

Publications (1)

Publication Number Publication Date
CO2023007904A2 true CO2023007904A2 (en) 2023-10-30

Family

ID=79686778

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0007904A CO2023007904A2 (en) 2020-12-18 2023-06-16 Lipocalin Mutein Dry Powder Formulation for the Treatment of Asthma

Country Status (13)

Country Link
EP (1) EP4262845A1 (en)
JP (1) JP2023553703A (en)
KR (1) KR20230121785A (en)
CN (1) CN116916945A (en)
AR (1) AR124436A1 (en)
AU (1) AU2021399151A1 (en)
CA (1) CA3199479A1 (en)
CL (1) CL2023001775A1 (en)
CO (1) CO2023007904A2 (en)
CR (1) CR20230265A (en)
IL (1) IL303729A (en)
TW (1) TW202241490A (en)
WO (1) WO2022129629A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
AU2007280398B2 (en) 2006-08-01 2012-05-10 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
EP2580236B1 (en) 2010-06-08 2019-04-03 Pieris Pharmaceuticals GmbH Tear lipocalin muteins binding il-4 r alpha
CN103998053B9 (en) 2011-12-13 2020-07-21 皮里斯制药有限公司 Methods for preventing or treating certain disorders by inhibiting binding of I L-4 and/or I L-13 to their respective receptors
MA55490A (en) 2019-03-29 2022-02-09 Astrazeneca Ab LIPOCALIN MUTEIN FOR THE TREATMENT OF ASTHMA
CN113939307A (en) * 2019-03-29 2022-01-14 皮里斯制药有限公司 Inhalation administration of lipocalin muteins

Also Published As

Publication number Publication date
WO2022129629A1 (en) 2022-06-23
IL303729A (en) 2023-08-01
JP2023553703A (en) 2023-12-25
KR20230121785A (en) 2023-08-21
CL2023001775A1 (en) 2024-01-19
CR20230265A (en) 2023-09-29
CN116916945A (en) 2023-10-20
AU2021399151A1 (en) 2023-07-27
TW202241490A (en) 2022-11-01
CA3199479A1 (en) 2022-06-23
EP4262845A1 (en) 2023-10-25
AR124436A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
UY31686A1 (en) NEW DOSAGE AND FORMULATION
CL2019003924A1 (en) Use of pridopidine for the treatment of functional decline. (divisional application 201900485).
CL2017003066A1 (en) Compositions of amorphous calcium carbonate for administration by inhalation, sublingual or buccal
UY30901A (en) NEW METHODS
ECSP21051833A (en) COMBINATION OF DEXTROMETORPHAN AND BUPROPION FOR THE TREATMENT OF DEPRESSION
BR112016018008A2 (en) BONE IMPLANT
CL2010000434A1 (en) Use of a pharmaceutical composition comprising vitamin b12 and n- (8- (2-hydroxybenzoyl) animo) caprylic acid or its salts to prepare a medicament useful in the treatment of vitamin b12 deficiency; pharmaceutical composition.
AR077573A2 (en) USE OF A TNF INHIBITOR AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
SV2008002855A (en) MILNACIPRAN FOR THE LONG-TERM TREATMENT OF THE FIBROMIALGIA SYNDROME
CL2011003003A1 (en) Reconstituted surfactant composition comprising a native surfactant protein c-analog polypeptide, a native surfactant protein-b-analog polypeptide, a monounsaturated phospholipid, and a saturated phospholipid, useful for the treatment of respiratory distress syndrome.
NZ710654A (en) Positioning, quick-release bioadhesion agent and use
TR201908938T4 (en) Formulations for the treatment of mouth, throat and respiratory ailments.
PA8784901A1 (en) USE OF AN ANTAGONIST PAR1 IN THE TREATMENT OF ATRIAL FIBRILATION
PE20211489A1 (en) PEDIATRIC DOSAGE FORMS OF VITAMIN D, METHODS OF PREPARATION AND USE
CO2020013427A2 (en) Cyclosporine formulations for use in the treatment of obliterative bronchiolitis syndrome (bos)
DOP2017000055A (en) ANAMORELINE BASED MEDICAL TREATMENTS
CO2023007904A2 (en) Lipocalin Mutein Dry Powder Formulation for the Treatment of Asthma
CO2022008001A2 (en) Methods for treating depressive disorders
EA200801824A1 (en) MEDICAL-PREVENTIVE COMPOSITION FOR CARE OF ORAL CAVITY
UY31097A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIONING AGENT
CO2023009085A2 (en) Levodopa dosage regimen
BR112018010497A2 (en) synergistic combination of pyrrolidone carboxylic acid and / or its salts and hyaluronic acid and / or its salts for use in the treatment and / or prevention of mucosal dryness and irritation and related pharmaceutical formulations
UY37907A (en) 3-PHENYLQUINAZOLIN-4 (3H) -UNES REPLACED AND ITS USES
BR112023003536A2 (en) ORAL TREATMENT COMPOSITIONS COMPRISING PRENYLATE FLAVONOIDS
BR112012007399A2 (en) oral care composition, uses of human recombinant interleukin-1 and methods for reducing bad breath and for the treatment or prevention of periodontal disease.